GABA promotes gastrin-releasing peptide secretion in NE/NE-like cells: Contribution to prostate cancer progression. by Solorzano, Susana R et al.
1ScIeNTIFIc REPORTS |  (2018) 8:10272  | DOI:10.1038/s41598-018-28538-z
www.nature.com/scientificreports
GABA promotes gastrin-releasing 
peptide secretion in NE/NE-like 
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In prostate cancer (PCa), neuroendocrine cells (NE) have been associated with the progression of the 
disease due to the secretion of neuropeptides that are capable of diffusing and influence surrounding 
cells. The GABAergic system is enriched in NE-like cells, and contributes to PCa progression. 
Additionally, γ-aminobutyric acid (GABA) stimulates the secretion of gastrin-releasing peptide (GRP) 
in peripheral organs. For the first time, in this study we show the role of GABA and GABAB receptor 1 
(GABBR1) expression in GRP secretion in NE-like prostate cancer cells. We demonstrated an increase 
in GRP levels in NE-like cell medium treated with GABAB receptor agonist. Moreover, the blocking 
of this receptor inhibited GABA-induced GRP secretion. The invasive potential of PC3 cells was 
enhanced by either GRP or conditioned medium of NE-like cells treated with GABA. Additionally, we 
confirmed a positive correlation between GABA and GRP levels in the serum of PCa patients with NE 
markers. Finally, using public available data sets, we found a negative correlation between GABBR1 
and androgen receptor (AR) expression, as well as a strong positive correlation between GABBR1 and 
enolase 2. These results suggest that GABA via GABBR1 induces GRP secretion in NE like cells involved 
in PCa progression.
Despite great efforts to improve treatment, prostate cancer (PCa) is the most frequently diagnosed cancer among 
men in developed countries1. Androgen ablation has been the main therapeutic intervention in managing 
hormone-sensitive prostate cancer2. However, in most cases, tumors tend to progress, despite treatment, to the 
castration-resistant prostate cancer (CRPC) stage. Once this occurs, the median survival rate is 18 to 24 months3. 
CRPC is a lethal stage, when prostate cancer progresses and metastasizes4.
Hormone-treated and hormone-refractory tumors can undergo neuroendocrine differentiation (NED)5,6. 
NED is characterized by an increase in a malignant subpopulation of cells with neuroendocrine (NE) features. 
Among CRPC tumors, it is estimated that 40–100% acquires NED. These tumors are referred to as neuroendo-
crine prostate cancer (NEPC)7,8. Experiments conducted in vitro and in vivo (animal models) have shown that 
prostate adenocarcinoma cells can transdifferentiate and acquire a NE phenotype through a process termed NE 
transdifferentiation9–12. These cells are typically referred to as “NE-like” cells, because their origin and biochemi-
cal characteristics are different from those of normal NE cells9,10. Wright et al. demonstrated that a knockdown of 
the androgen receptor (AR) in LNCaP cells induced a NE-like morphology and expression of NE markers. Those 
findings suggested that AR activity repressed the transdifferentiation process11.
NE transdifferentiation in PCa revealed an epithelial plasticity that gave rise to tumor adaptation in response 
to AR-targeted therapies. A recent study showed that NEPC occurred in 30/81 patients with CRPC. Moreover, 
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AR expression was low in these tumors12. Although NE cells and NE-like cells do not express AR13, they can 
secrete many types of neuropeptides, like gastrin-releasing peptide (GRP), serotonin, and neurotensin, and they 
express NE markers, such as enolase 2 (ENO2), chromogranin A, and chromogranin B6,14. Hence, understanding 
the molecular etiology of NEPC and identifying novel therapeutic targets are of utmost importance, particularly 
because, at present, no effective therapy is available.
Neuropeptides, such as GRP, have been positively associated with PCa progression15. GRP, a 27-amino 
acid neuropeptide, is the mammalian homologue of the peptide known as bombesin, which was isolated from 
frog skin16. Neuroendocrine cells in tumors are considered the main source of GRP. In PCa, GRP stimulates 
mitogen-stimulated proliferation, migration, and invasion, through autocrine and paracrine signaling17,18. Studies 
have shown that serum GRP concentrations were elevated in patients with advanced PCa. Specifically, GRP con-
centrations were significantly elevated in advanced metastatic and CRPC tumors, but not in the early cancer 
stages19.
The Gordon group created transgenic mice (CR2-TAg) that developed a pattern of NEPC initiation and 
progression. Prostate samples from CR2-Tag mice were compared to prostate samples from normal mice with 
GeneChip arrays to identify candidate mediators of NE cell differentiation. One candidate gene was glutamic acid 
decarboxylase (Gad1 in mouse, GAD1 in human), which showed 40-fold higher expression in NEPC than in nor-
mal NE cells20,21. The GAD1 enzyme produces the most abundant inhibitory neurotransmitter in the mammalian 
brain: γ-aminobutyric acid (GABA). GABA plays a tissue-specific function22–28, and it is widespread throughout 
periphery organs, including the prostate.
The above-mentioned study also showed that GABA levels were enriched in NE-like cells, compared to nor-
mal NE cells. Likewise, NE-like cells expressed functional GABAB receptors (GABBR1), which regulated the 
invasion of PCa cells and promoted matrix metalloproteinase (MMP) expression29–31. GABBR1 is a metabotropic 
G-protein-coupled receptor that mediates the inhibitory effects of GABA; these effects play crucial roles in hepa-
tocellular and pancreatic carcinomas32. However, how GABA participates in the invasion of PCa cells remains 
unknown.
GABA has been reported to regulate the release of neuropeptides and hormones in different peripheral organs. 
For instance, it governs somatostatin and glucagon secretion in pancreatic beta cells33; and in the stomach, it reg-
ulates the secretion of gastrin, somatostatin, and GRP by endocrine cells34. In this study, we investigated the role 
of GABA in GRP secretion in NE/NE-like cells derived from PCa samples, and its impact in PCa progression. We 
demonstrated that GABA, through GABBR1, induced GRP secretion. The results suggested that GABA might be 
a central player in regulating PCa progression when tumors lack the AR.
Results
Establishment of a NE-like cell line with siRNA-mediated AR silencing in LNCaP cells. Wright 
et al. reported that an AR knockdown induced neuronal-specific expression of proteins, like ENO2, which led 
to a NE phenotype in LNCaP cells11. We decided to use AR-specific siRNA in LNCaP cells to establish a NE cell 
model. LNCaP cells transfected with an AR-specific siRNA exhibited successful AR mRNA knockdown at 24 h to 
96 h (>70% knockdown) compared to cells transfected with control siRNA (*p < 0.0001; Fig. 1a). At the protein 
level, AR could not be detected at 96 h (**p < 0.01); in contrast, AR protein levels remained unchanged in con-
trol cells (Fig. 1b). Furthermore, we confirmed that the AR knockdown led to an elevation in the ENO2 content 
(***p < 0.001). GRP was also evaluated as a NE protein, as previously described35. We observed that GRP protein 
levels were also elevated in AR-silenced cells (*p < 0.05 and ***p < 0.001) (Fig. 1b). These results confirmed the 
hypothesis of a potential link between AR inactivation and the increased frequency of NE cells in androgen-in-
dependent tumors11.
Presence of GABA in LNCaP cells after knocking down AR with siRNA. It has been reported that 
GABA and its receptor were present at higher levels in NEPC cells, compared to other prostate cell types30. This 
observation prompted to examine whether GABA was present in LNCaP cells after the AR knockdown. Thus, 
at 96 h, we found that AR levels decreased and GABA levels increased. We also observed that the AR knock-
down induced morphological changes in LNCaP cells. At 96 h, cells showed increases in protrusions and 
extended processes (Fig. 2). Control siRNA did not lead to any morphology changes or changes in GABA levels 
(Supplementary Fig. 2). Taken together, our results suggested that the acquisition of the NE phenotype was linked 
to an increase in GABA levels and a decrease in AR expression in LNCaP cells.
Secretion of GABA vesicles from NE-like cells mediated by GABBR1. Interestingly, we found that 
LNCaP cells were able to secrete GABA vesicles 96 hours after the AR-knockdown (Fig. 3a, Supplementary Fig. 3). 
To evaluate further whether NE-like cells secreted GABA, we used HPLC to measure GABA levels in the cell 
extracts and conditioned medium of AR-knockdown and control cells at 96 h. We found increased GABA levels 
in cell extracts of AR-knockdown LNCaP cells (*p < 0.01; Fig. 3b), but not in the conditioned medium of cells 
transfected with control siRNA (**p < 0.001; Fig. 3b).
We then assessed the expression of GABAB receptors, based on evidence from previous reports, which sug-
gested that these receptors were implicated in promoting metastasis, particularly in NEPC tumors12,36. GABBR1 
expression was induced by ~1.2-fold at 72 h after AR-knockdown in LNCaP cells. This expression level was main-
tained until 96 h after silencing (*p < 0.0001; Fig. 3c). In contrast, GABBR2 mRNA levels did not change with the 
AR-knockdown in LNCaP cells (Supplementary Fig. 4). The GABBR1 protein content increased by ~0.8-fold at 
96 h (*p < 0.05) (Fig. 3d), when AR was undetectable. Thus, we showed that both GABA levels and GABABR1 
expression were elevated in NE-like cells.
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Regulation of GRP by exogenous and endogenous GABA-GABBR1 in NE-like cells. We explored 
whether GABBR1 participated in the secretion of GRP (involved in cell invasion), as described previously in stud-
ies on stomach endocrine cells34,36,37. We studied the expression of GABBR1 in NE-like and control cells treated 
with baclofen. The expression of GABBR1 in NE-like cells increased with increases in baclofen concentrations 
(*p < 0.0001; Fig. 4a). In a Western blot analysis, the GABBR1 content was elevated in NE-like cells treated with 
10 and 100 µM of baclofen (*p < 0.001; Fig. 4b). Moreover, the GRP concentration was higher in the medium 
of NE-like cells treated with baclofen compared to that of control cells (Fig. 4c). To confirm the role of GABAB 
receptor in GRP secretion, we exposed NE-like cells and control cells to the GABAB receptor antagonist, CPG 
35348 (10, 50, and 100 µM), for 12 h, combined with baclofen (100 µM). We observed that CPG 35348 blocked 
the baclofen effects on GRP secretion. In fact, at the highest concentration, CPG 35348 inhibited GRP secretion 
(Fig. 4d). These results suggested that GABBR1 activation stimulated GRP secretion in NE-like cells.
Figure 1. Establishment of NE-like cell line by siRNA targeted to the AR silence in LNCaP cell. (a) AR mRNA 
expression levels were analyzed by RT-qPCR in LNCaP cells transfected with AR-specific siRNA and control 
siRNA from 24 h to 96 h in RPMI supplemented with 10% FBS. Experiments were repeated four times. Differences 
among groups were compared by two-tailed unpaired Student’s t test, *p < 0.0001. (b) Upper panel, Representative 
Western blot analysis of AR, ENO2 and GRP expression in LNCaP cells transfected with AR-specific siRNA and 
Control siRNA from 24 h to 96 h. GPDH was used as a loading control. Lower panel, ImageJ software was used 
for densitometric quantification of proteins. Graphs represent the mean ± SEM (n = 3) *p < 0.05, **p < 0.01 and 
***p < 0.001 compared to the control group. The samples derive from the same experiment and that gels/blots 
were processed in parallel. Full-length blots/gels are presented in Supplementary Fig. 1.
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Modification in the invasive capacity of PC3 cells by conditioned medium from NE-like 
cells. We collected conditioned media from NE-like and control cells treated with or without 100 µM of 
baclofen for 12 h. With a Boyden chamber assay, we evaluated whether the conditioned media could modify the 
invasive capacity of PC3 cells. We applied synthesized GRP as a positive control for inducing invasion. The upper 
chamber contained PC3 cells (6 × 104) suspended in 200 µl of culture medium. The lower chamber contained 
700 µl of either conditioned medium or GRP (positive control). Samples were incubated for 6 h, as described pre-
viously38. We found that PC3 cell invasion was significantly augmented by the conditioned medium from NE-like 
cells (Fig. 5a). Interestingly, incubation in the conditioned medium from NE-like cells without baclofen treatment 
significantly increased PC3 cell invasion compared to conditioned medium from control cells (Fig. 5a).
In addition, we incubated PC3 cells with 35% of conditioned medium from either NE-like cells or control 
cells, treated with and without baclofen (100 µM) for 24 h. We performed RT-qPCR on cell extracts, and found 
a significant increase in GRPR expression in PC3 cells treated with conditioned medium from baclofen-treated 
NE-like cells (Fig. 5b). These results suggested that GRP secreted by NE-like cells increased PC3 invasion by 
Figure 2. GABA expression is induced in NE-like cells. Fluorescence immunohistochemistry was performed 
to examine GABA and AR content in LNCaP cells transfected with AR-specific siRNA from 24 to 96 h. An anti-
GABA antibody (green staining), anti-AR antibody (red staining) and 4,6-diamidino-2-phenylindole (DAPI) 
were used. GABA levels were increased after AR silencing. Morphological changes can be seen as well. The 
proportion of LNCaP cells with obvious protrusions showed an increase once GABA levels were increased and 
AR was silenced.
www.nature.com/scientificreports/
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activating GRPR in AR-deficient cells. Similar results were observed in AR-knockdown LNCaP cells at 96 h, when 
they were stimulated with the conditioned medium described above (Supplementary Fig. 5).
Positive correlations between GABA and GRP levels in patients with NE characteristics. To 
investigate whether GABA and GRP levels were correlated, we evaluated serum samples from ten patients with 
PCa. We observed a positive correlation between GABA and GRP levels in all samples (correlation coefficient 
[r] = 0.894; p = 0.0004). The mean ± SEM serum concentrations were: GRP, 88.92 ± 35.91 pg/ml; and GABA, 
5.33 ± 2.8 pmol/10 µl. When the samples were separated into two groups according to their characteristics, the 
group with NE characteristics showed the strongest positive correlation (r = 0.961; p = 0.03; Fig. 6a).
We also measured levels of AR, ENO2, and GABBR1 in urine samples from patients with PCa (n = 10) and 
patients with Benign Prostatic Hyperplasia (BPH) (n = 5). The NEPC group displayed the lowest AR levels, 
compared to the other two groups (PCa and BPH) (Fig. 6b). The NEPC group also displayed elevated ENO2 
expression (*p < 0.05; Fig. 6c) and elevated GABBR1 mRNA levels (**p < 0.001; Fig. 6d). As a control for the 
diagnosis of PCA, PCA3 expression was assessed with RT-qPCR in urine samples from patients with BPH and 
PCa (*p < 0.05; Fig. 6e)39. Keeping in mind the limited number of samples, these results pointed to a strong cor-
relation between GABA and GRP in patients with NE characteristics.
Correlations between GABBR1 and AR and GABBR1 and ENO2 expression in NEPCs. To evalu-
ate further the role of GABBR1 in PCa progression to NEPC, we analyzed AR mRNA levels, AR protein levels, and 
GABBR1 gene expression in The Cancer Genome Atlas Research Network data set40. Interestingly, we observed 
Figure 3. Secretion of GABA vesicles in NE-like cells mediated by GABBR1. (a) Representative immunofluorescence 
detection of GABA vesicles (green staining) at 96 h in AR siRNA LNCaP cells. The presence of these vesicles was 
associated with the reduction in AR expression and the display of the neuroendocrine phenotype. Vesicles are 
indicated by arrows; anti-AR antibody (red staining) and 4,6-diamidino-2-phenylindole (DAPI) were used; (b) 
GABA levels were evaluated by HPLC in 96 h LNCaP cells transfected with AR-specific siRNA and control siRNA 
from an aliquot of total lysate proteins and conditioned medium. Experiments were repeated three times. Differences 
among groups were compared by two-tailed unpaired Student’s t test, *p < 0.01 and **p < 0.001; (c) GABBR1 mRNA 
expression levels were examined by RT-qPCR in LNCaP cells transfected with AR-specific siRNA and control siRNA. 
Experiments were repeated three times. Differences among groups were compared by two-tailed unpaired Student’s t 
test, *p < 0.0001. (d) Western blot analysis of GABBR1 after transfection with AR-specific siRNA and control siRNA 
from 24 h to 96 h. GPDH was used as a loading control; representative blots are shown of three replicated experiments 
(Upper panel). Intensity of the bands was quantified with ImageJ software and GABBR1/GPDH is shown in the bar 
graph (Lower panel) *p < 0.05. The samples derive from the same experiment and that gels/blots were processed in 
parallel. Full-length blots/gels are presented in Supplementary Fig. 1.
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a significant negative correlation between the expression of GABBR1 and AR, at the protein level (r = 0.179; 
p = 0.03; n = 146; Fig. 7a, left) and at the mRNA level (r = −0.274; p = 0.003677−4; n = 333; Fig. 7a, right) in 
primary PCa tissues. In addition, we examined a data set12 that included CRPC (n = 34) and NEPC (n = 15) 
samples to assess the regulation of GABBR1 in NED. Importantly, we found a highly significant positive correla-
tion between the expression of GABBR1 and a NE marker (ENO2) in NEPC samples (r = 0.539; p = 0.03; n = 15; 
Fig. 7b) compared to CRPC samples (r = 0.223; p = 0.22; n = 32; Fig. 7b). Moreover, we observed that AR mRNA 
levels were indeed down-regulated in NEPC compared to CRPC (Fig. 7c), ENO2 expression was upregulated in 
NEPC compared to CRPC (Fig. 7c), and GABBR1 expression was similar in NEPC and CRPC (Fig. 7c). These 
results suggested a negative relationship between GABBR1 and AR expression in patients with PCa, but a positive 
relationship between GABBR1 and ENO2 expression (a neuronal marker) in patients with NEPC.
Discussion
This study aimed to unveil the role of GABA in the secretion of GRP, mediated by GABBR1, in NE/NE-like cells 
from PCa samples. We showed that both endogenous and exogenous GABA could stimulate GRP secretion in 
NE/NE-like cells. This stimulation promoted invasion in AR-deficient cells.
There is a strong relationship between alterations in AR (both mRNA and protein) levels and the progression 
of PCa adenocarcinoma to NEPC. Certainly, a large number of studies have shown that, under selective pressure 
of potent AR inhibition in PCa adenocarcinoma cells, NE-like cells transdifferentiated to form a more aggressive 
tumor41–43. Recently, Beltran et al., demonstrated that divergent NEPC evolution occurred in association with 
reduced AR expression, in one or more CRPC cells, through either linear or independent clonal evolution12. 
Wright et al. showed that AR was required to repress the NE transdifferentiation process in PCa cells in vitro, 
Figure 4. GABA promotes GRP secretion mediated by GABBR1 in NE-like cells. (a) GABBR1 mRNA 
expression was evaluated by RT-qPCR of 96 h AR siRNA cells and 96 h control siRNA cells grown for 12 h in 
RPMI with indicated concentrations of baclofen. Differences among groups were compared by two-tailed 
unpaired Student’s t test, *p < 0.0001. (b) GABBR1 protein expression was evaluated by Western Blot in whole 
cell lysate. GAPDH was used as a loading control. Graphs represent the mean ± SEM (n = 4), *p < 0.001. The 
last result was normalized to 1 with respect to the vehicle. The concentrations of GRP in the medium of 96 h AR 
siRNA cells and 96 h control siRNA cells were examined by ELISA (n = 3/group). (c) GRP was present in the 
medium of both cells incubated with RPMI containing different concentrations of Baclofen (GABAB agonist) 
1, 10 and 100 µM for 12 h. Differences among groups were compared by two-tailed unpaired Student’s t test, 
*p < 0.001 and **p < 0.0001. (d) GABAB antagonist (CGP 35348) was used, and cells were treated with 10, 50 
and 100 µM in combination with baclofen (100 µm) for 12 h. Differences among groups were compared by two-
tailed unpaired Student’s t test, *p < 0.001 and **p < 0.0001. The samples derive from the same experiment and 
that gels/blots were processed in parallel. Full-length blots/gels are presented in Supplementary Fig. 1.
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and they suggested that AR might actively repress an analogous NE transdifferentiation process in PCa cells in 
vivo. Following this methodology, we also confirmed that, in most cases, transdifferentiation was associated with 
reduced AR expression11. Moreover, we demonstrated that NE-like cells expressed NE markers, such as ENO2 
and GRP. We also found elevated levels of GABA after knocking down AR in cells. Moreover, NE-like cells could 
secrete GABA vesicles, which enriched the conditioned medium, compared to the conditioned medium of con-
trol cells.
GABA and its receptors, GABAA and GABAB, have been identified in NE-like cells derived from PCa sam-
ples21. Likewise, enriched GABA levels were found in NE cells and in primary tumors, compared to normal 
prostate tissues, in transgenic mice with NEPC. Also, elevated GABA levels were found in the serum of transgenic 
mice compared to that of normal mice30. Furthermore, we detected higher GABBR1 mRNA and protein levels in 
NE-like cells, which implied that GABBR1 might play a role in the GABAergic pathway of NE-like cells. In addi-
tion, the GABAB receptor was implicated in PCa metastasis, because it promoted MMP production36, metastatic 
spread, and treatment resistance, which was strongly associated with NEPC44.
Another important characteristic of tumors that display NED is the production of NE peptides, such as GRP, 
which play an important role in the development of castration resistance18,37. Studies have revealed that exoge-
nous and endogenous GABA can stimulate the secretion of peptides such as gastrin, somatostatin and GRP in rat 
stomach34. Our results gave rise to the hypothesis that GABA and GRP secretion might be regulated by GABBR1 
activity in NE-like PCa cells. Indeed, a GABAB antagonist inhibited the elevation in GRP levels induced by 
baclofen in NE-like cells. We showed that this regulation was mediated by GABBR1, also we found that baclofen 
increases the mRNA and protein expression of GABBR1 in a dose-dependent manner, in NE-like cells. In future 
studies, it would be interesting to test whether the GABAA receptor might be implicated in neuropeptide secre-
tion, because it has been shown that GABAA regulates proliferation in PCa45.
GRP has been identified as a potent paracrine and autocrine growth factor in PCa. Moreover, GRP promoted 
PCa cell migration and protease expression46,47. We noticed higher invasiveness rates mediated by GRPR. This 
effect was induced by GRP obtained from NE-like cells’ conditioned medium. This finding supported a correla-
tion between NE differentiation and the increased metastatic potential of androgen-insensitive prostate cancers. 
Keep in mind that cancer invasion is a critical step that leads to the lethality associated with metastasis.
Another important finding from our study was the strong correlation we found between GABA and GRP in 
the serum of patients with PCa, particularly in serum that contained NE markers. Four out of ten patients dis-
played lower AR and higher ENO2 gene expression levels than the levels observed in the PCa and the BPH groups, 
consistent with patients with NEPC in previous studies12,48. Moreover, the same four patients showed elevated 
GABBR1 mRNA levels.
Patients with NEPC exhibited a higher Gleason score.Azuma et al. observed that patients with PCa metastasis 
had higher Gleason scores and higher prostate GABA levels compared to patients with PCa without metastasis 
Figure 5. The conditioned medium of NE-like cells modifies the invasive capacity of PC3 cells through GRPR. 
(a) Invasion assay was performed by using a Boyden chamber. PC3 cells (6 × 104) suspended in 200 µl of culture 
medium without FBS were placed in the upper chamber. 700 µl of conditioned medium from 96 h Control 
siRNA and 96 h AR siRNA treated with or without baclofen (100 µM) was added in the lower chamber for 
6 h. Results are represented as mean ± SEM of three independent experiments in triplicate wells, *p < 0.05, 
**p < 0.001 and ***p < 0.0001. (b) GRPR mRNA expression was analyzed by RT-qPCR. Results are presented 
as mean ± SEM of three independent experiments in triplicate, *p < 0.05 **p < 0.001 and ***p < 0.0001. GRP 
synthetized was used as positive control; the previous concentration represents 35% of conditioned medium 
from 96 h AR siRNA treated with baclofen (100 µM) that was used to perform the experiments.
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and patients with BPH36. Yashi et al. found that patients that displayed resistance to androgen blockage showed 
elevated ProGRP levels in the serum. They also demonstrated that ProGRP levels in a subset of patients tended 
to increase when the cancer became androgen independent, but remained unchanged or decreased during the 
androgen-dependent stage19. It would be interesting to follow our patients with NEPC, who displayed elevated 
GABBR1 and ENO2 gene expression levels, to evaluate the cancer progression. This study was the first to find a 
direct correlation between GABA and GRP levels, particularly in the NEPC group. However, a larger number of 
samples would be necessary to provide a more robust statistical analysis.
We found a novel negative association between GABBR1 and AR expression in PCa. Functionally, we showed 
that AR was downregulated and GABBR1 was upregulated in NE-like cells of PCa samples derived from patients 
that expressed serum NE markers. Furthermore, we confirmed that these genes were negatively correlated in a 
PCa data set from primary tumors. As mentioned above, the presence of NED implicated reduced AR activity 
and/or expression. Multiple studies have suggested that genes involved in NEPC progression were accompanied, 
or controlled, by the loss of AR expression and/or activity49. Consistent with our finding of this negative correla-
tion, we observed a high positive correlation between GABBR1 and ENO2 expression in NEPC samples. GABBR1 
was expressed in both CRPC and NEPC, although the expression was greater in NEPC. This result might be 
explained by the fact that, among the samples included in the NEPC group, some had low AR-signaling and a low 
NEPC classification score12.
Overall, our results confirmed a negative correlation between GABBR1 expression and AR (protein and 
mRNA) expression. It is well known that, once CRPC progresses to NEPC, PCa cells lose the AR, which makes 
them resistant to any drug that targets the AR35. GABBR1 may represent a new therapeutic strategy for treating 
late-stage castrate-resistant tumors that have lost the AR and have acquired a NE phenotype. Based on our results, 
we propose that GABBR1 is expressed when cells have a well-defined NE phenotype, which includes the presence 
of NE markers and low AR expression.
In conclusion, our results suggested that GABA, through GABBR1 activation in NE-like cells, induced GRP secre-
tion, which in turn, increased cell invasion. The exact molecular mechanism through which the GABA/GABBR1 
axis is involved in GRP secretion remains an important field of study and requires further investigation. However, 
we believe the results of this study will contribute to a better understanding of NEPC tumors.
Figure 6. GABA levels are positively correlated with GRP levels in patients with NE markers. (a) A positive 
correlation between GABA and GRP levels was found in PCa patients (r = 0.894; p = 0004; n = 10), and when 
patients were separated, PCa-NE patients had a strong positive correlation (r = 0.961; p = 0.03; n = 4). (b–d) 
Relative AR, ENO2 (*p < 0.05), GABBR1 (**p < 0.001) gene expression in BPH vs. PCa and BPH vs. PCa-NE, 
respectively. AR mRNA levels were not significantly different between groups. (e) PCA3 mRNA levels were 
significantly higher in PCa patients compared to BPH patients (*p < 0.05).
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Methods
Cells culture and treatment. The human prostate adenocarcinoma cell lines LNCaP and PC3 were 
obtained from the American Type Culture Collection (ATCC) used with passage number between 10 and 
12. LNCaP was cultured in RPMI-1640 medium (Sigma-Aldrich), and PC3 was grown in DMEM medium 
(Corning). Both media contained 10% Fetal Bovine Serum (FBS) (Corning). Cells were maintained at 37 °C 
under 5% CO2. Baclofen at 1, 10 and 100 µM for 12 h (Sigma-Aldrich) was used to activate GABAB receptor, and 
CGP 35348 (Sigma-Aldrich) for antagonizing GABAB receptor. Cancer cells were pretreated with receptor antag-
onist for 2 h at concentrations of 10, 50 and 100 µM, to inhibit GRP secretion, and then incubated with GABA 
(100 µM) for 12 h.
Small interfering RNA (siRNA) transfection. LNCaP cells (2 × 105) were grown in phenol-red free 
RPMI medium (Sigma-Aldrich). Then, cells were transfected with Silencer select (Life Technologies) siRNA tar-
geting AR (siRNA ID: s1538) and Negative control (siRNA ID: AM4615) using DharmaFECT 2 transfection 
reagent (Dharmacon) as described by manufacturer’s instructions. siRNAs final concentration was 12.5 nM per 
experiment. Cells were harvested every 24 h for 96 h.
Patient cohort. A total of 10 male Mexican patients, being treated at the Hospital General Dr. Manuel 
Gea Gonzalez (Mexico City, Mexico) between July 2012 and February 2013, were enrolled in the present study. 
Written informed consent was obtained from all patients. The protocol of the present study was approved by the 
ethics committee of Hospital General Dr. Manuel Gea Gonzales (No.CIEI/144/12), project registration number 
(28-53-2012). All experiments and methods were performed according to these relevant guidelines and regula-
tions. All patients presented palpable nodules or induration of the prostate [suspicious digital rectal examina-
tion (DRE)] and blood levels of PSA > 2.5 ng/ml. Subsequently, an experienced pathologist assessed the cores to 
determine whether the biopsy specimens were malignant. For those samples pathologically diagnosed as PCa, 
Gleason scoring was performed by careful examination of the microscopic pattern of the cancer foci. The control 
group comprised 6 patients with Benign Prostatic Hyperplasia (BPH), whose biopsy specimens contained benign 
glands and normal prostate cells. Blood and urine samples were obtained. Patient’s clinical and pathological data 
were collected (Table 1).
Figure 7. GABBR1 is negatively correlated with AR expression and positively correlated with ENO2 expression 
in NEPC. (a) GABBR1 and AR expression are negatively correlated at protein level, left panel (r = −0.179; 
p = 0.03; n = 146) and mRNA level, right panel (r = −0.274; p = 0.003677−4; n = 333). Previously published 
prostate cancer gene and protein expression data set40 was acquired from cBioPortal51,52. GABBR1 and AR 
expression values were retrieved and plotted. Previously published RNA-seq of 49 CRPC12 with or without 
neuroendocrine differentiation was obtained from cBioPortal51,52. (b) GABBR1 and ENO2 mRNA expression 
are positively correlated in NEPC group (r = 0.539; p = 0.03; n = 15) compared to CRPC group (r = 0.223; 
p = 0.22; n = 32). (c) The AR, ENO2 and GABBR1 expression values were plotted comparing NEPC to CRPC.
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Urine sample processing and RNA extraction. Urine sample processing was performed as described39. 
The collected urine with prostate fluid was mixed with 5 ml RNAlater buffer (Qiagen) as an RNA stabilizing agent. 
RNA extraction was performed using the RNeasy Mini kit (Qiagen) according to manufacturer’s guidelines.
Real-time RT-PCR assay. Total RNA from cell lines was isolated using an RNeasy kit (Qiagen) according to 
manufacturer’s instructions. A total of 800 ng from cell lines and 250 ng from urine samples [as described previ-
ously39] of RNA were reverse transcribed in a thermal cycler using SuperScript II (Invitrogen) according to manu-
facturer’s instructions. All reagents for TaqMan PCR, including AR (Hs00171172_ml), GAPDH (Hs02758991_gl), 
KLK3 (Hs01105076_m1), PCA3 (Hs01371939_g1), GABBR1 (Hs00559488_m1), GRPR (Hs01055872_m1), 
ENO2 (Hs00157360_m1) were purchased from Life Technologies. Reactions were run in a 96-well plate format 
using a Viia 7 Real Time PCR-System (Life Technologies). The quantitative real-time PCR results were analyzed 
using the 2−∆∆Ct method, using GAPDH as housekeeping gene.
Protein extraction and Western blot analysis. Cells were lysed with RIPA buffer (Sigma-Aldrich) 
with added protease inhibitors (Sigma-Aldrich). Proteins were obtained by centrifugation at 12,500 rpm at 
4 °C for 30 min and quantified using an EZQ Protein Quantitation Kit (Life Technologies) according to man-
ufacturer’s instructions. Proteins (30 µg) were separated by electrophoresis on SDS-PAGE (Bio-Rad). SeeBlue 
Plus2 (Invirogen) was used for sizing and visualization of the gel running pattern and protein transfer. Resolved 
proteins were transferred on immobilon PVDF membranes (Millipore) at 20 V for 30 min. Membranes were 
air-dried, wet with methanol, washed with TBS-T and blocked at 4 °C overnight in 1% (w/v) non-fat skimmed 
milk/TBS-T. Membranes were incubated with antibodies against AR (1:500 ab108341), GABBR1 (1:500 ab75239) 
from ABCAM, GAPDH (1:20000 5174 s), ENO2 (1:200 9536 s) obtained from Cell Signaling and GRP (1:500 
sc-271045) from Santa Cruz Biotechnology at 4 °C overnight.
Blots were then incubated with anti-rabbit secondary antibody (1:5000 ab99697) obtained from ABCAM or 
anti-mouse secondary antibody (1:300 7076 s) from Cell Signaling conjugated to horseradish peroxidase (HRP) 
at room temperature (RT) for 2 h. Chemiluminescence signals were detected using ChemiDoc XRS system 
(BioRad). Western immunoblots were quantified using ImageJ software.
Immunofluorescence. LNCaP cells were transfected as mentioned above, cells were collected every 24 h for 
96 h. Next, cells were fixed with 4% (v/v) paraformaldehyde, permeabilized with1% (v/v) Triton X-100. Then, cells 
were blocked with 1% bovine serum albumin in PBS for 2 hat RT and labeled with rabbit polyclonal anti-GABA 
(1:100 A2052; Sigma-Aldrich) for 1 hat RT and mouse monoclonal anti-AR (1:50 ab9474; ABCAM) overnight at 4 °C 
in PBS. The anti-GABA antibody was detected with an Alexa Fluor 488 donkey anti-rabbit antibody (Invitrogen), 
and the anti-AR antibody was detected with an Alexa Fluor 568 anti-mouse antibody (Invitrogen), incubated for 
1 h. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI) (Invitrogen). Immunohistochemistry was 
observed using a Confocal Microscope (Zeiss LSM 510 Axiovert 200 M Laser Scanning).
Preparation of conditioned medium (CM). In order to collect conditioned medium (CM), LNCaP-siAR 
and LNCaP-Control were incubated in phenol-red free RPMI culture medium with different concentrations of 
Baclofen (1, 10, 100 and 500 µM), or vehicle (sterile water) in a humidified incubator for 12 h, after 96 h of trans-
fection. CM was collected and centrifuged at 2000 g for 10 min at 4 °C; medium was filtered through a 0.2 µm 
nylon filter; then, protease inhibitors (Sigma-Aldrich) were added and immediately used or frozen at −80 °C 
until needed.
Pt. Age Gleason score PSA (ng/ml) Surgery Hormone therapy
Benign prostate hyperplasia
1 62 − 3.3 Prostatectomy −
2 75 − 5.65 Prostatectomy −
3 68 − 6.5 Prostatectomy −
4 72 − 5.53 Prostatectomy −
5 65 − 16.2 Prostatectomy −
Prostate cancer
A 65 3 + 3 4.87 Prostatectomy −
B 65 4 + 4 12 TURP −
C 64 4 + 4 4.5 TURP −
D 83 5 + 4 31 TURP +
E 80 3 + 3 8.4 TURP +
F 74 3 + 3 16.0 TURP −
G*◆ 64 4 + 4 147 − +
H* 76 4 + 3 160 − +
I* 74 3 + 3 32 TURP +
J* 77 3 + 3 30 TURP +
Table 1. Clinical features. *Prostate cancer patients with NE characteristics; ◆Castration-resistant prostate 
cancer patient; PSA, prostate-specific antigen.
www.nature.com/scientificreports/
1 1ScIeNTIFIc REPORTS |  (2018) 8:10272  | DOI:10.1038/s41598-018-28538-z
Enzyme-linked immunosorbent assay (ELISA). ELISA was used to quantify GRP concentrations 
in conditioned medium and serum patients. Serum samples were separated using ultra centrifuge filters 3 K 
(Amicon). In brief, analyses were performed in 96-well polyvinyl chloride (PVC) microtiter plates (Maxisorp, 
Nunc). Plates were coated at 4 °C overnight with conditioned medium. Plates were washed three times 
(PBS-Tween solution) and then non-specific sites were blocked with bovine serum albumin at 37 °C for 2 h. 
After one washing step, a monoclonal antibody specific for GRP human (0.5 µg/ml; GenScript) was added to the 
plates at 4 °C overnight. Plates were washed and the Anti-rabbit secondary antibody (1:8000 ab99697, ABCAM) 
conjugated to horseradish peroxidase (HRP) was incubated at RT for 2 h. After another wash, final reaction was 
determined by adding 100 µl of freshly prepared peroxidase substrate solution (TMB-ELISA; Thermo Scientific). 
Enzyme was blocked with 100 µl H2SO4·2 N. The optical density was measured at 450 nm using an Epoch 
Microplate spectrophotometer. GRP concentrations were determined according to a standard curve from syn-
thesized peptide (GRP; GeneScript), and results were given in pg/ml.
Invasion assay. Cell invasion assay was performed in a transwell chamber (24-well, 8μm pore size; Corning), 
with the bottom coated with 1 mg/ml BD Matrigel Matrix (BD Biosciences). PC3 and LNCaP cells were 
re-suspended in serum free DMEM medium, and 200 µl of the cell suspension (6 × 104) was supplemented to the 
upper chamber membranes. 700 µl of indicated conditioned medium was put into the lower chamber as a che-
moattractant. After 6 h or 24 h of PC3 and LNCaP cells incubation at 37 °C in a 5% CO2 humidified atmosphere, 
respectively, non-invaded cells on the surface of the membrane were removed with a cotton swab. Cells that had 
invaded through the filter to the lower surface were fixed with 4% paraformaldehyde and stained with 0.5% crys-
tal violet. Each experiment was performed 3 times in triplicate. The number of invading cells was counted in 4 
fields within each trans-well. Determination of the number of invaded cells was performed using ImageJ software.
Amino acid analysis. The levels of GABA in total lysate proteins and conditioned medium were measured 
by HPLC as described previously by Salazar et al.50. An aliquot was used for protein determination and perchlo-
ric acid (0.6% final concentration) was added to the homogenates. Protein was sedimented in a microfuge. The 
supernatant was neutralized with KOH and centrifuged again to sediment the precipitated potassium perchlorate. 
Amino acids were derivatized with O-phthalaldehyde and after 3 min 20 µl were injected into a Beckman liquid 
chromatograph, using a reverse phase ODS column (25 cm + 4 mm) and a linear gradient (from 25% to 75% 
methanol) of a methanol mixture: 0.1 mM potassium acetate buffer, pH 5.5. The Amino acids were fluorometri-
cally detected, and the identification and quantitation of peaks were compared according to their retention times 
taking into account standards for amino acid mixtures and additional internal standards.
Statistical analysis. Gene and protein expression levels from RT-qPCR, Western blot and data from inva-
sion assay experiments were analyzed in Graph Pad 6.0 using the two-tailed unpaired Student t-test when com-
paring two groups and a one-way ANOVA for several groups at once. To assess the correlation between GABBR1 
expression and AR (with gene and protein expression from TCGA and from our independent patient cohort) 
a test for association between paired samples, using Pearson’s product moment correlation coefficient was per-
formed. In this context, correlation of CRPC and NEPC was assessed jointly as well as independently. The R lan-
guage for statistical computing (http://www.R-project.org) was used for this analysis and statistical significance 
was assigned at p < 0.05.
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